BRCA1 and breast cancer: Therefore, considering only average, published penetrance estimates for the counselling of BRCA1/2 PV carriers typically seen in genetic clinics may underestimate BC risks—a scenario equivalent to the predictions in cohort-1, when using only BRCA1 and BRCA2 PV status.